Benzoyl Peroxide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329303

CAS#: 94-36-0

Description: Benzoyl Peroxide, also known as Bepio and CD-1579, is a bactericidal agent, peroxide derivative that has been used topically for burns and as a dermatologic agent in the treatment of acne and poison ivy dermatitis. Benzoyl Peroxide is used also as a bleach in the food industry.


Price and Availability

Size
Price

100g
USD 150
1kg
USD 750
Size
Price

200g
USD 250
2kg
USD 1250
Size
Price

500g
USD 450

Benzoyl Peroxide (wetted with 25% water), purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329303
Name: Benzoyl Peroxide
CAS#: 94-36-0
Chemical Formula: C14H10O4
Exact Mass: 242.0579
Molecular Weight: 242.23
Elemental Analysis: C, 69.42; H, 4.16; O, 26.42


Synonym: Benzoyl Peroxide; CD-1579; M-6050; CD 1579; M 6050; CD1579; M6050; Bepio; NeoBenz

IUPAC/Chemical Name: benzoic peroxyanhydride

InChi Key: OMPJBNCRMGITSC-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H10O4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10H

SMILES Code: O=C(OOC(C1=CC=CC=C1)=O)C2=CC=CC=C2


Technical Data

Appearance:
Solid powder

Purity:
75% (wetted with 25% water)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Lamel SA, Sivamani RK, Rahvar M, Maibach HI. Evaluating clinical trial design:
systematic review of randomized vehicle-controlled trials for determining
efficacy of benzoyl peroxide topical therapy for acne. Arch Dermatol Res. 2015
Nov;307(9):757-66. doi: 10.1007/s00403-015-1568-9. Review. PubMed PMID: 26048131.

2: Vaccaro M, Guarneri F, Borgia F, Pollicino A, Altavilla G, Cannavò SP.
Efficacy, tolerability and impact on quality of life of clindamycin phosphate and
benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in
patients with metastatic colorectal cancer. J Dermatolog Treat.
2016;27(2):148-52. doi: 10.3109/09546634.2015.1086478. PubMed PMID: 26313697.

3: Smith TJ, Foegeding EA, Drake M. Sensory and Functionality Differences of Whey
Protein Isolate Bleached by Hydrogen or Benzoyl Peroxide. J Food Sci. 2015
Oct;80(10):C2153-60. doi: 10.1111/1750-3841.13000. PubMed PMID: 26317318.

4: Smith TJ, Gerard PD, Drake MA. Effect of temperature and concentration on
benzoyl peroxide bleaching efficacy and benzoic acid levels in whey protein
concentrate. J Dairy Sci. 2015 Nov;98(11):7614-27. doi: 10.3168/jds.2015-9890.
PubMed PMID: 26364115.

5: Weiss J, Stein Gold L, Leoni M, Rueda MJ, Liu H, Tanghetti E. Customized
Single-agent Therapy Management of Severe Inflammatory Acne: A Randomized,
Double-blind, Parallel-group, Controlled Study of a New Treatment--Adapalene
0.3%-Benzoyl Peroxide 2.5% Gel. J Drugs Dermatol. 2015 Dec;14(12):1427-35. PubMed
PMID: 26659936.

6: Kircik LH. The role of benzoyl peroxide in the new treatment paradigm for
acne. J Drugs Dermatol. 2013 Jun 1;12(6):s73-6. PubMed PMID: 23839205.

7: Morimoto H, Kikukawa Y, Murakami N. [Pharmacological profiles and clinical
effects of benzoyl peroxide gel as treatments for acne vulgaris]. Nihon
Yakurigaku Zasshi. 2015 Oct;146(4):225-32. doi: 10.1254/fpj.146.225. Japanese.
PubMed PMID: 26656967.

8: Kawashima M, Hashimoto H, Alio Sáenz AB, Ono M, Yamada M. Is benzoyl peroxide
3% topical gel effective and safe in the treatment of acne vulgaris in Japanese
patients? A multicenter, randomized, double-blind, vehicle-controlled,
parallel-group study. J Dermatol. 2014 Sep;41(9):795-801. doi:
10.1111/1346-8138.12580. PubMed PMID: 25132461.

9: Rehman K, Tan CM, Zulfakar MH. Development and in-vitro characterization of
fish oil oleogels containing benzoyl peroxide and salicylic acid as keratolytic
agents. Drug Res (Stuttg). 2014 Mar;64(3):159-65. doi: 10.1055/s-0033-1355351.
PubMed PMID: 24026957.

10: Bircher A, Friederich NF, Seelig W, Scherer K. Allergic complications from
orthopaedic joint implants: the role of delayed hypersensitivity to benzoyl
peroxide in bone cement. Contact Dermatitis. 2012 Jan;66(1):20-6. doi:
10.1111/j.1600-0536.2011.01996.x. PubMed PMID: 22085108.

11: Keating GM. Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in
the treatment of acne vulgaris in patients aged ≥ 12 years. Am J Clin Dermatol.
2011 Dec 1;12(6):407-20. doi: 10.2165/11208170-000000000-00000. Review. PubMed
PMID: 21967116.

12: Baumann LS, Oresajo C, Yatskayer M, Dahl A, Figueras K. Comparison of
clindamycin 1% and benzoyl peroxide 5% gel to a novel composition containing
salicylic acid, capryloyl salicylic acid, HEPES, glycolic acid, citric acid, and
dioic acid in the treatment of acne vulgaris. J Drugs Dermatol. 2013
Mar;12(3):266-9. PubMed PMID: 23545907.

13: Dhawan SS, Gwazdauskas J. Clindamycin phosphate 1.2%-benzoyl peroxide (5% or
2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis. 2013
Feb;91(2):99-104. PubMed PMID: 23513559.

14: Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of
rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol. 2014
Jun;13(6):685-8. PubMed PMID: 24918558.

15: El-Latif AA, Hassan FA, Elshahed AR, Mohamed AG, Elsaie ML. Intense pulsed
light versus benzoyl peroxide 5% gel in treatment of acne vulgaris. Lasers Med
Sci. 2014 May;29(3):1009-15. doi: 10.1007/s10103-013-1440-0. PubMed PMID:
24114421.